Study of Epigenetic and Inflammatory Markers of Accelerated Biological Ageing in the Follow up of Patients With Hodgkin's Lymphoma

Study of Epigenetic and Inflammatory Markers of Accelerated Biological Ageing in the Follow-up of Patients With Hodgkin's Lymphoma in Complete Remission for at Least 2 Years

Study design: It is a monocentric and exploratory study, experimental on human tissues in vitro which involves the analysis of peripheral blood in patients with Hodgkin's lymphomas with the following characteristics:

• in complete remission for at least two years after first-line therapy with stage IIb, III or IV at onset (Ann Arbor classification).
• newly diagnosed (stage IIb, III or IV, Ann Arbor Classification).

The study aims to evaluate patients with hodgkin lymphoma in complete remission for at least 2 years and newly diagnosed (stage II b, stage III or stage IV) as they are currently characterised by a long life expectancy during which there is an increased and early incidence of non-neoplastic systemic complications as well as, of course, manifestations of secondary malignancies.

Inclusion Criteria:

• hodgkin lymphoma stage II b, III or IV at onset in remission for at least two years after the first line of therapy for lymphoma
• Newly diagnosed histologically confirmed stage II b, III or IV patients who require first-line therapy
• Patients of both sexes aged ≥ 18 years at enrollment
• Signature of informed consent

Exclusion Criteria:

• Concomitant second neoplasm